
An experimental antibody therapy for multiple sclerosis can cut symptom flare-ups by half, versus a standard treatment, a new clinical trial has found. The drug, called ublituximab, beat a standard oral medication for MS in reducing patients’ relapses — periods of new or worsening symptoms. It also proved better at preventing areas of inflammatory damage… read on > read on >